Md. biopharm gets $1M NIH grant to study drug

Neuralstem Inc., a biopharmaceutical company, recently received a grant worth up to nearly $1 million from the National Institutes of Health. The Germantown company received the research grant, to evaluate over two years the ability of its small molecule compound, NSI-189 to prevent and treat diabetic neuropathy. In a previous study, NSI-189 was shown to significantly protect motor and sensory nerve function ...

To purchase a reprint of this article, contact reprints@thedailyrecord.com.